Back to Stakeholders
Categories

2 domains / 5 areas / 3 specializations

Research, Drug Development & Manufacturing
Academic & Non-Profit ResearchIndependent Academic Research Groups
Research, Drug Development & Manufacturing
Media, Education & Engagement
Educational Platforms & ResourcesOnline Resources
Media & CommunicationConferences & Events
Media, Education & Engagement

MIND Foundation

Also known as: MIND, MIND - European Foundation for Psychedelic Science, MIND European Foundation for Psychedelic Science, MIND Foundation gGmbH, MIND Foundation

Germany
1 Trial1 Paper

European nonprofit research and implementation organization that organizes the INSIGHT Conference and allied public/professional events.

Academic Research

1 papers

Published Papers

1

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Mar 18, 2026

Quick Facts

Type
Non-Profit
HQ
Germany
Website
Visit

Collaborated Trials

1
CompletedII

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Start Date
Compounds
Placebo, Psilocybin

Research Papers

1
Open AccessindividualPrimary

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

In this triple‑blind, active placebo‑controlled randomised trial (n=144) of adults with treatment‑resistant depression, two 25 mg doses of psilocybin plus adjunct psychotherapy produced clinically meaningful reductions in depressive symptoms on exploratory secondary measures but did not significantly improve the pre‑second‑dose HAMD17 response rate versus nicotinamide.

Published
Journal
JAMA Psychiatry
Authors
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., Ströhle, A., Scharf, D., Spangemacher, M., Wolff, M., Assadi, Z., Bahri, S., Becher, L., Färber, L. V., Kirchen, N., Kulakova, E., Kunz, L., Meijer, A., Rohrmoser, B., Wellek, S., Berger, M. M., Gründer, G.